Clinical Trials

614 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT02595931 2026-04-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

66 enrolled

GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT06958328 2026-04-08

LAP100

356 enrolled

Pancreatic Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

104 enrolled

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT06998940 2026-03-27

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

94 enrolled

Pancreatic Neoplasms

NCT02047474 2026-03-06

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Phase 2 Completed

46 enrolled 15 charts

Pancreatic Neoplasms

NCT02890355 2026-03-05

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

123 enrolled 15 charts

Pancreatic Neoplasms

NCT04683315 2026-03-05

PANCREAS

84 enrolled

Pancreatic Neoplasms

NCT02021422 2026-02-18

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Phase 1 Completed

13 enrolled

Phase 3 Active not recruiting

Pancreatic Neoplasms

NCT04340141 2026-02-10

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

358 enrolled

Pancreatic Neoplasms

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

35 enrolled

Pancreatic Neoplasms

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

25 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Pancreatic Neoplasms

NCT04640480 2026-01-27

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Phase 1 Completed

21 enrolled

Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03977233 2026-01-13

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

45 enrolled

Phase NA Not yet recruiting

Pancreatic cancer, adult, Pancreatic Neoplasms

NCT07325214 2026-01-12

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

136 enrolled

Pancreatic Neoplasms

NCT03322995 2026-01-08

PANC

125 enrolled

Pancreatic Neoplasms

NCT03443492 2025-12-30

Pancreas

Phase 2 Completed

130 enrolled

Pancreatic Neoplasms

NCT05391126 2025-12-16

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Phase NA Recruiting

178 enrolled

Phase 3 Active not recruiting

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06625320 2025-12-12

RASolute 302

501 enrolled

Pancreatic Neoplasms

NCT04753879 2025-12-04

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

38 enrolled

Pancreatic Neoplasms

NCT06941857 2025-12-03

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

20 enrolled

Carcinoma, Pancreatic Neoplasms

NCT05417386 2025-11-18

FOLFIRINOX + NIS793 in Pancreatic Cancer

Phase 1 Terminated

4 enrolled

Phase 1/2 Active not recruiting

Pancreatic Neoplasms

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

120 enrolled

Pancreatic Neoplasms

NCT03184870 2025-10-09

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

332 enrolled 44 charts

Pancreatic Neoplasms, Colorectal Neoplasms

NCT04141995 2025-08-07

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

Phase 2 Terminated

11 enrolled

Pancreatic Neoplasms

NCT04594772 2025-07-02

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

32 enrolled

Phase 1/2 Active not recruiting

Pancreatic Neoplasms

NCT04581473 2025-06-05

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

192 enrolled

Pancreatic Neoplasms, Stomach Neoplasms

NCT06897644 2025-05-25

PANThEON

340 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT03750669 2025-05-13

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Phase 3 Completed

324 enrolled

Phase EARLY_PHASE1 Completed

Pancreatic Neoplasms

NCT02896907 2025-04-30

Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

8 enrolled 9 charts